Peptide · Fact sheet
Bremelanotide
Also known as Vyleesi · PT-141
Bremelanotide is FDA approved for a specific diagnosis: acquired, generalized hypoactive sexual desire disorder in premenopausal women when the low desire is not explained by another condition, relationship problem, or medication. It is not approved to enhance sexual performance or for use in men or postmenopausal women.
What is Bremelanotide?
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors involved in central nervous system signaling.
Its approval is tied to a defined diagnosis, population, product, and outcome—not the broader online label PT-141.
Benefits people look for
It is an unusual approved peptide that acts through central desire pathways rather than directly changing blood flow.
Online claims often erase the label's population limits and significant cardiovascular, nausea, and pigmentation warnings.
What the evidence supports
- Phase 3 trials found modest average improvements in sexual desire and distress compared with placebo in the labeled population.
- The clinical goal is diagnosis-specific improvement, not a general enhancement claim.
All research areas
- Hypoactive sexual desire disorder
- Sexual desire and related distress
- Melanocortin signaling
- Other sexual-function populations outside the approved label
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.
We do not fill this gap with unsourced testimonials or estimated success rates.
Side effects & risks
- The label warns about transient increases in blood pressure and reductions in heart rate and contraindicates use with uncontrolled hypertension or known cardiovascular disease.
- Nausea was common in pivotal trials; flushing, headache, vomiting, and injection-site reactions also occurred.
- Focal hyperpigmentation may occur and did not always resolve after stopping treatment in studies.
- The product can affect absorption of some oral medicines through delayed gastric emptying.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Strong human evidence for approved usesTwo randomized Phase 3 trials support the scoped indication, with improvements in desire and distress measures. Evidence does not establish a universal libido or performance effect.
Selected research to read
Peer-reviewed report of the two pivotal randomized trials.
FDA approval & research status
Vyleesi is FDA approved for acquired, generalized hypoactive sexual desire disorder in specified premenopausal women. The label explicitly excludes sexual-performance enhancement and use in men or postmenopausal women.
Approved uses covered here
- Acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women under the Vyleesi label
FDA approved for a specific sexual-desire disorder indication
Bremelanotide is approved under the Vyleesi label for a defined indication and population. That status does not make it a general libido, mood, or performance treatment.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Benefit-risk balance in populations outside the label
- How well average trial changes translate into meaningful benefit for an individual
- Long-term outcomes with broader or more frequent exposure than studied
The takeaway
Bremelanotide is an approved peptide medicine, but the approved use is much narrower than the online PT-141 conversation. Diagnosis, population, cardiovascular risk, and the exact label matter.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA prescribing information: Vyleesi
Official indication, limitations, contraindications, warnings, and adverse reactions.
- 2fdaFDA multidisciplinary review: Vyleesi
FDA's clinical and regulatory assessment supporting the approval.
- 3